Drug Store News10d
Celltrion launches Stelara biosimilar
Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...
Yahoo Finance2d
Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...
JD Supra8d
Celltrion Launches STEQEYMA® (ustekinumab-stba) in the United States
Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...
Business Wire9d
Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi ® (ustekinumab-aauz)
--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar ...
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...